e-learning
resources
London 2016
Sunday, 04.09.2016
Latest insights into functional capacity and muscle weakness in chronic lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A systematic review and meta-analysis of the effect of dual versus mono- long-acting bronchodilator therapy on exercise endurance in COPD
Bhavesh Popat (Leicester, United Kingdom), Bhavesh Popat, Sally Majd, Michael Steiner, Charlotte Bolton, Rachael Evans
Source:
International Congress 2016 – Latest insights into functional capacity and muscle weakness in chronic lung diseases
Session:
Latest insights into functional capacity and muscle weakness in chronic lung diseases
Session type:
Thematic Poster
Number:
710
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Bhavesh Popat (Leicester, United Kingdom), Bhavesh Popat, Sally Majd, Michael Steiner, Charlotte Bolton, Rachael Evans. A systematic review and meta-analysis of the effect of dual versus mono- long-acting bronchodilator therapy on exercise endurance in COPD. Eur Respir J 2016; 48: Suppl. 60, 710
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Triple therapy
versus
single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis
Source: Eur Respir J, 52 (6) 1801586; 10.1183/13993003.01586-2018
Year: 2018
Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: Two randomised clinical trials
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Metronome-paced hyperventilation, CT measurements and exercise to investigate dynamic hyperinflation contrasting tiotropium versus indacaterol treatment in moderate COPD patients
Source: International Congress 2015 – Unravelling the mechanisms of symptoms and exercise limitationas in disease
Year: 2015
The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015
Effect of “add-on” interventions on exercise training in individuals with COPD: a systematic review
Source: ERJ Open Res 2016
Year: 2016
Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study
Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation
Year: 2013
Comparison of protective effect of bronchodilators in COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Therapeutic validity and effectiveness of supervised physical exercise in patients with COPD - A systematic review and meta-analysis
Source: International Congress 2015 – Respiratory physiotherapy assessment and techniques in COPD and asthma
Year: 2015
Medication use in COPD: systematic review and meta-analysis
Source: Annual Congress 2007 - Treatment and care of COPD
Year: 2007
LABA/LAMA combination, exercise and lung hyperinflation in COPD: a meta-analysis
Source: International Congress 2017 – COPD management
Year: 2017
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Triple therapy versus dual bronchodilation and long-acting ß-agonists/inhaled corticosteroids in COPD: accumulating evidence from network meta-analyses
Source: International Congress 2019 – Therapeutic breakthrough Year in review
Year: 2019
Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept